Reynders McVeigh Capital Management LLC Has $10.61 Million Stock Position in Novartis AG (NYSE:NVS)
Reynders McVeigh Capital Management LLC Has $10.61 Million Stock Position in Novartis AG (NYSE:NVS)
Reynders McVeigh Capital Management LLC grew its position in Novartis AG (NYSE:NVS – Get Rating) by 1.7% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 139,608 shares of the company's stock after buying an additional 2,387 shares during the period. Reynders McVeigh Capital Management LLC's holdings in Novartis were worth $10,612,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Activest Wealth Management acquired a new position in shares of Novartis in the 3rd quarter valued at $26,000. Carolinas Wealth Consulting LLC lifted its position in Novartis by 146.7% in the 2nd quarter. Carolinas Wealth Consulting LLC now owns 370 shares of the company's stock valued at $31,000 after acquiring an additional 220 shares in the last quarter. Creative Financial Designs Inc. ADV lifted its position in Novartis by 42.7% in the 3rd quarter. Creative Financial Designs Inc. ADV now owns 441 shares of the company's stock valued at $34,000 after acquiring an additional 132 shares in the last quarter. Curi Wealth Management LLC bought a new stake in Novartis in the 2nd quarter valued at $46,000. Finally, Adirondack Trust Co. lifted its position in Novartis by 327.7% in the 3rd quarter. Adirondack Trust Co. now owns 556 shares of the company's stock valued at $42,000 after acquiring an additional 426 shares in the last quarter. Institutional investors and hedge funds own 8.12% of the company's stock.
Get Novartis alerts:Novartis Stock Performance
NYSE:NVS traded down $2.33 during mid-day trading on Thursday, reaching $85.90. 385,656 shares of the company's stock were exchanged, compared to its average volume of 2,160,289. Novartis AG has a one year low of $74.09 and a one year high of $94.26. The firm has a market capitalization of $190.06 billion, a PE ratio of 9.07, a price-to-earnings-growth ratio of 2.17 and a beta of 0.52. The business's fifty day simple moving average is $90.68 and its two-hundred day simple moving average is $84.76. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.07 and a current ratio of 1.31.
Analysts Set New Price Targets
Several equities research analysts have commented on NVS shares. Barclays cut their price target on shares of Novartis from CHF 85 to CHF 75 in a research report on Friday, October 14th. StockNews.com started coverage on shares of Novartis in a research report on Wednesday, October 12th. They set a "strong-buy" rating on the stock. UBS Group boosted their price target on shares of Novartis from CHF 82 to CHF 84 and gave the stock a "neutral" rating in a research report on Wednesday, December 14th. Stifel Nicolaus raised shares of Novartis from a "hold" rating to a "buy" rating in a research report on Monday, December 5th. Finally, Morgan Stanley lowered shares of Novartis from an "equal weight" rating to an "underweight" rating in a research note on Friday, January 6th. Three analysts have rated the stock with a sell rating, seven have given a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $85.11.About Novartis
(Get Rating)
Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals.
Read More
- Get a free copy of the StockNews.com research report on Novartis (NVS)
- The Bottom Is In For Meta Platforms, Volatility Is Not Over
- Analyzing Alaska Air's Recent Earnings
- Apple's Earnings, Expectations and Surprises
- T-Mobile Delivers Where it Matters Most to Investors
- Exxon Mobil Could Gush To New Highs Very Soon
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS – Get Rating).
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.
根据雷德斯麦克维资本管理有限责任公司提交给美国证券交易委员会的最新文件,其在诺华制药(纽约证券交易所代码:NVS-GET评级)的头寸在第三季度增加了1.7%。该公司持有139,608股该公司股票,在此期间又购买了2,387股。截至最近一个季度末,Reynders McVeigh Capital Management LLC持有的诺华股份价值10,612,000美元。
其他机构投资者和对冲基金最近也对他们在该公司的头寸进行了调整。Activest Wealth Management在第三季度收购了价值2.6万美元的诺华股票的新头寸。Carolinas Wealth Consulting LLC在第二季度将其在诺华的头寸提高了146.7%。Carolinas Wealth Consulting LLC现在持有该公司370股股票,价值3.1万美元,上个季度又购买了220股。创新金融设计公司ADV在第三季度将其在诺华的头寸提高了42.7%。Creative Financial Designs Inc.ADV在上个季度增持了132股后,现在持有441股该公司股票,价值3.4万美元。Curi Wealth Management LLC在第二季度购买了诺华的新股份,价值4.6万美元。最后,阿迪朗达克信托公司在第三季度将其在诺华的持仓提高了327.7%。Adirondack Trust Co.目前持有该公司556股股票,价值42,000美元,上一季度又购入了426股。机构投资者和对冲基金持有该公司8.12%的股票。
到达诺华公司警报:诺华公司股票表现
纽约证券交易所:NVS周四午盘交易中下跌2.33美元,至85.90美元。该公司股票成交量为385,656股,而其平均成交量为2,160,289股。诺华制药的一年低点为74.09美元,一年高位为94.26美元。该公司的市值为1900.6亿美元,市盈率为9.07倍,市盈率为2.17倍,贝塔系数为0.52倍。该业务的50日简单移动均线切入位为90.68美元,200日简单移动均线切入位为84.76美元。该公司的负债权益比率为0.32,速动比率为1.07,流动比率为1.31。
分析师设定新的价格目标
几位股票研究分析师对NVS的股票发表了评论。巴克莱银行在10月14日星期五的一份研究报告中将诺华公司的股票目标价从85瑞士法郎下调至75瑞士法郎。StockNews.com在10月12日星期三的一份研究报告中开始报道诺华的股票。他们对该股设定了“强力买入”评级。瑞银集团在12月14日星期三的一份研究报告中将诺华公司的股票目标价从82瑞士法郎上调至84瑞士法郎,并给予该股“中性”评级。Stifel Nicolaus在12月5日星期一的一份研究报告中将诺华公司的股票评级从持有上调至买入。最后,摩根士丹利在1月6日星期五的一份研究报告中将诺华公司的股票评级从“持平”下调至“减持”。三位分析师对该股的评级为卖出,七位分析师给出了持有评级,三位分析师给出了买入评级,一位分析师对该公司给予了强烈的买入评级。根据MarketBeat.com的数据,该股目前的平均评级为持有,平均目标价为85.11美元。诺华公司简介
(获取评级)
诺华制药是一家控股公司,从事保健品的开发、制造和营销。它通过以下细分市场运作:创新药物、Sandoz和公司。创新药品部门研究、开发、制造、分销和销售专利药品,由两个业务部门组成:诺华肿瘤和诺华制药。
阅读更多内容
- 免费获取StockNews.com关于诺华(Novartis)的研究报告
- Meta平台的底部已经到了,波动性还没有结束
- 阿拉斯加航空公司近期收益分析
- 苹果的收益、预期和惊喜
- T-Mobile在对投资者最重要的领域提供服务
- 埃克森美孚可能很快创下新高
想看看其他对冲基金持有哪些NVS吗?访问HoldingsChannel.com获取诺华制药(纽约证券交易所代码:NVS-GET Rating)的最新13F文件和内幕交易信息。
接受诺华日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对诺华和相关公司的最新新闻和分析师评级的每日简要摘要。
译文内容由第三方软件翻译。
风险及免责提示
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧